PET-MR bei Patienten mit Glioblastoma multiforme

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Der Radiologe

• Publication date

  2013-08-16

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00117-013-2500-yPMID 23949437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Classic models for dynamic contrast‐enhanced MRI

  2013cited by this paper
• Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer

  2013cited by this paper
• Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI

  2012cited by this paper
• Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability

  2012cited by this paper
• MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

  2012cited by this paper
• Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI

  2012cited by this paper
• Diffusion, confusion and functional MRI

  2012cited by this paper
• Quantification of Perfusion and Permeability in Multiple Sclerosis: Dynamic Contrast-Enhanced MRI in 3D at 3T

  2012cited by this paper
• Einführung in die Grundlagen und Techniken der Diffusionsbildgebung

  2011cited by this paper
• Diffusionsgewichtung in der Neuroradiologie

  2011cited by this paper
• MRI-Assisted PET Motion Correction for Neurologic Studies in an Integrated MR-PET Scanner

  2011cited by this paper
• On the scope and interpretation of the Tofts models for DCE‐MRI

  2011cited by this paper
• [Introduction to the basic principles and techniques of diffusion-weighted imaging].

  2011cited by this paper
• Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.

  2011cited by this paper
• FET-PET for malignant glioma treatment planning.

  2011cited by this paper
• Molecular imaging of gliomas with PET: opportunities and limitations.

  2011cited by this paper
• Correlation of 6-18F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas

  2010cited by this paper
• Absolute quantification of perfusion using dynamic susceptibility contrast MRI: pitfalls and possibilities

  2010cited by this paper
• New advances that enable identification of glioblastoma recurrence

  2009cited by this paper
• Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas

  2009cited by this paper
• Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma

  2009cited by this paper
• Quantification of cerebral blood flow, cerebral blood volume, and blood–brain‐barrier leakage with DCE‐MRI

  2009cited by this paper
• Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Methyl-l-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma

  2009cited by this paper
• Measurement of brain perfusion, blood volume, and blood‐brain barrier permeability, using dynamic contrast‐enhanced T1‐weighted MRI at 3 tesla

  2009cited by this paper
• Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

  2009cited by this paper
• Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography.

  2009cited by this paper
• Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.

  2009cited by this paper
• Dynamic contrast‐enhanced quantitative perfusion measurement of the brain using T1‐weighted MRI at 3T

  2008cited by this paper
• Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography

  2008cited by this paper
• Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.

  2008cited by this paper
• Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature

  2008cited by this paper
• Complementary but Distinct Roles for MRI and 18F-Fluoromisonidazole PET in the Assessment of Human Glioblastomas

  2008cited by this paper
• 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma

  2008cited by this paper
• Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy

  2008cited by this paper
• Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.

  2007cited by this paper
• Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.

  2006cited by this paper
• 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.

  2006cited by this paper
• Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques.

  2006cited by this paper
• 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.

  2005cited by this paper
• Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation.

  2005cited by this paper
• O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.

  2005cited by this paper
• Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

  2005cited by this paper
• Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas

  2005cited by this paper
• Optimal role of temozolomide in the treatment of malignant gliomas

  2005cited by this paper
• Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas

  2005cited by this paper
• Imaging hypoxia and angiogenesis in tumors.

  2005cited by this paper
• Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.

  2004cited by this paper
• [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.

  2004cited by this paper
• Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

  2004cited by this paper
• Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value

  2004cited by this paper
• Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

  2003cited by this paper
• Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO).

  2002cited by this paper
• Molecular imaging of cancer with positron emission tomography

  2002cited by this paper
• The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery

  2001cited by this paper
• Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.

  2000cited by this paper
• PET in differentiation of recurrent brain tumor from radiation injury.

  2000cited by this paper
• Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging.

  1999cited by this paper
• Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols

  1999cited by this paper
• Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo.

  1999cited by this paper
• Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?

  1998cited by this paper
• Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

  1998cited by this paper
• Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors

  1997cited by this paper
• 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET.

  1997cited by this paper
• Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.

  1997cited by this paper
• 18‐fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma

  1997cited by this paper
• Expression of Integrin avß3 in Small Blood Vessels of Glioblastoma Tumors

  1996cited by this paper
• Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

  1996cited by this paper
• Serial FDG‐PET Studies in the Prediction of Survival in Patients with Primary Brain Tumors

  1993cited by this paper
• Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo?

  1993cited by this paper
• Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.

  1992cited by this paper
• Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine.

  1991cited by this paper
• [11C]L-methionine uptake in gliomas.

  1989cited by this paper
• Positron emission tomography in patients with glioma a predictor of prognosis

  1988cited by this paper
• The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms.

  1986cited by this paper
• Positron emission tomography imaging of regional cerebral glucose metabolism.

  1986cited by this paper
• Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography

  1982cited by this paper
• Sugar and amino acid transport by cells in culture--differences between normal and malignant cells.

  1972cited by this paper
• A medical treatment for gallstones?

  1972cited by this paper
• Non-invasive Measurement of Perfusion: a Critical Review of Arterial Spin Labelling Techniques

  year unknowncited by this paper

• Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences

  2017cites this paper
• Brain Tumors: An Update on Clinical PET Research in Gliomas.

  2017cites this paper
• Prediction of CT Substitutes from MR Images Based on Local Diffeomorphic Mapping for Brain PET Attenuation Correction

  2016cites this paper
• Self-assembled 20-nm (64)Cu-micelles enhance accumulation in rat glioblastoma.

  2015cites this paper